Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease

Chronic kidney disease (CKD) affects 1 in 10 members of the general population, placing these patients at an increasingly high risk of kidney failure. Despite the significant burden of CKD on various healthcare systems, there are no effective cures that reverse or even halt its progression. In recen...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yifang, Ricardo, Sharon D., Samuel, Chrishan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181689/
https://www.ncbi.nlm.nih.gov/pubmed/35682717
http://dx.doi.org/10.3390/ijms23116035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181689/
https://www.ncbi.nlm.nih.gov/pubmed/35682717
http://dx.doi.org/10.3390/ijms23116035

Ejemplares similares